# ♣ ACTICOAT<sup>◊</sup>and ACTICOAT 7

### Antimicrobial Barrier Dressings

Application guide

## **Smith**Nephew

Helping you get CLOSER TO ZERO<sup>⋄</sup> wound infection





### Dressing codes

Dressing	Ordering code	Size	Carton
ACTICOAT			
	66000808	5cm x 5cm	5
	66000791	10cm x 10cm	12
	66000792	10cm x 20cm	12
	66000793	20cm x 40cm	6
	66000794	40cm x 40cm	6
	66000795	10cm x 120cm roll	6
ACTICOAT 7			
	66000809	5cm x 5cm	5
	66000796	10cm x 12.5cm	5
	66000797	15cm x 15cm	5





For detailed product information, including indications for use, contraindications, effects, precautions, warnings, and important safety information, please consult product's Instructions for Use (IFU) prior to use.

Smith & Nephew Pty Ltd Australia T +61 2 9857 3999 F +61 2 9857 3900

www.smith-nephew.com/australia

Smith & Nephew Ltd New Zealand T +64 9 820 2840 F +64 9 820 2841

www.smith-nephew.com/new-zealand

♦ Trademark of Smith+Nephew All Trademarks acknowledged © May 2020 Smith+Nephew AWM-AWD-24913-anz 0520

#### References


1. Smith+Nephew 2008. Antimicrobial activity of ACTICOAT FLEX 3 against a broad spectrum of wound pathogens. Internal report. DOF 0810016. 2. Smith+Nephew 2008. Antimicrobial activity of ACTICOAT FLEX 3 Dressings in a 3 day repeat challenge test. Internal report. DOF 0810017. 3. Smith+Nephew 2017. Silver release properties of ACTICOAT Dressings. Internal report. DS/16/363/R2. 4. Smith+Nephew 2008. Silver release testing of Project Andorra (7 day) dressings. Internal report. DS/08/062/R1. 5. Westaim Biomedical 2000.Long term comparative evaluation of Silverlon and ACTICOAT 7 dressings activities against MRSA. Fort Saskatchewan, Alberta, Canada. Report - 001213. 6. Westaim Biomedical 2001.Seven day efficacy of ACTICOAT 7 Dressing against multiple organisms. Fort Saskatchewan, Alberta, Canada. Report - 010322.

## ♣ ACTICOAT<sup>◊</sup> and ACTICOAT 7 Antimicrobial Barrier Dressings

#### **Indications**

- ACTICOAT and ACTICOAT 7 dressings are indicated as absorbent antimicrobial barrier dressings for use over partial and full thickness wounds such as pressure ulcers, venous ulcers, diabetic injuries, burns and recipient graft sites.
- ACTICOAT and ACTICOAT 7 dressings may be used on infected wounds. Where the product is used on infected wounds, the infection should be inspected and treated as per local clinical protocol.
- Please refer to Instructions for Use before using the product.







# ♣ Instructions for application

Where required, wound cleansing should be performed according to local clinical protocol. DO NOT use saline.

- 1. Remove ACTICOAT 7 dressing from the package using a clean technique.
- Moisten the dressing according to local clinical protocol (DO NOT use saline). Remove excess water prior to application e.g. leave to drain on a sterile field for approximately 2 minutes.
- 3. Cut the dressing to shape as necessary. When used with compression therapy, the dressing must be cut to the size of the wound. (ACTICOAT 7 only).



4. Apply the dressing to the wound surface.



5. Secure the ACTICOAT / ACTICOAT 7 dressing in place with an appropriate secondary dressing that will maintain a moist wound environment.

In the case of highly exuding wounds an absorbent secondary dressing is appropriate. In this type of wound, film dressings are not recommended.

Keep the dressing moist, but not so wet that tissue maceration occurs.





Change the dressing depending on the amount of exudate present and the condition of the wound

The ACTICOAT dressing's antimicrobial activity remains effective for up to 3 days<sup>1-3</sup> and ACTICOAT 7 dressing's remains effective for up to 7 days.<sup>4-6</sup>





Pressure Ulcer on the Sacrum: Applying and Removing ACTICOAT and ACTICOAT 7



**Diabetic Foot Ulcer:** Applying and
Removing ACTICOAT
and ACTICOAT 7



# → ACTICOAT<sup>◊</sup> and ACTICOAT 7 Antimicrobial Barrier Dressings

#### Precautions/Warning

- For external use only.
- ACTICOAT and ACTICOAT 7 dressings are not compatible with oil-based products, such as petrolatum.
- Avoid contact with electrodes or conductive gels during electronic measurements e.g. EEG and ECG.
- Do not use if product colour is not uniform.
- Occasionally transient pain on application of ACTICOAT and ACTICOAT 7 dressings have been reported. This can be minimized by carefully following the application instructions. Should continuous pain be experienced after application remove the dressing and discontinue use.
- ACTICOAT and ACTICOAT 7 dressings should only be used on premature infants of less than 37 weeks gestation when the clinical benefit outweighs potential risks.
   No clinical data is available in this age group and only limited data is available for use in neonates.
- ACTICOAT and ACTICOAT 7 dressings are single use only products. If used on more than one patient, cross-contamination or infection may occur. In addition, the antimicrobial properties of the product will be compromised.
- Opening the dressing pack compromises the sterile barrier therefore any unused dressing should not be retained for application at a later date.

#### Contraindications

- Do not use on patients with a known sensitivity to silver.
- Do not use on a patient undergoing MRI (magnetic resonance imaging) examination. In patients undergoing MRI, ACTICOAT dressings must be removed from the area within the anatomical field being imaged. If an ACTICOAT dressing is being used on an area not within the image field it may remain in place during the MRI.
- Prior to administering radiation therapy, remove ACTICOAT and ACTICOAT 7 dressings. A new dressing can be applied following treatment.



For a complete list of precautions, contraindications, indications please consult the Instructions for Use (IFU)